JP2023511471A5 - - Google Patents
Info
- Publication number
- JP2023511471A5 JP2023511471A5 JP2022523943A JP2022523943A JP2023511471A5 JP 2023511471 A5 JP2023511471 A5 JP 2023511471A5 JP 2022523943 A JP2022523943 A JP 2022523943A JP 2022523943 A JP2022523943 A JP 2022523943A JP 2023511471 A5 JP2023511471 A5 JP 2023511471A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- exist
- alkyldiyl
- iii
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19205545 | 2019-10-28 | ||
| EP19205545.7 | 2019-10-28 | ||
| PCT/US2020/057356 WO2021086785A1 (en) | 2019-10-28 | 2020-10-26 | Bifunctional compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511471A JP2023511471A (ja) | 2023-03-20 |
| JP2023511471A5 true JP2023511471A5 (cg-RX-API-DMAC7.html) | 2023-10-31 |
Family
ID=68382246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523943A Pending JP2023511471A (ja) | 2019-10-28 | 2020-10-26 | 二官能性化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230002367A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054724A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023511471A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114599428A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021086785A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| JP7508578B2 (ja) * | 2020-04-06 | 2024-07-01 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| JP2024533990A (ja) | 2021-08-09 | 2024-09-18 | ジェネンテック, インコーポレイテッド | Brmの調節に使用するためのフェノール誘導体 |
| JP2025502782A (ja) * | 2021-12-28 | 2025-01-28 | ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム | がん治療剤としての強力かつ選択的なsmarca2分解キメラ分子 |
| JP2025506452A (ja) * | 2022-02-09 | 2025-03-11 | オーリジーン オンコロジー リミテッド | Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物 |
| AU2023292503A1 (en) * | 2022-06-15 | 2024-10-31 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
| CN119384414A (zh) * | 2022-06-30 | 2025-01-28 | 甘李药业股份有限公司 | 一种用作smarca2/4抑制剂的化合物及其应用 |
| WO2024064328A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2024064316A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| WO2025096976A1 (en) * | 2023-11-01 | 2025-05-08 | Cornell University | Arid1a is a prognostic marker for aggressive lymphoma transformation and presents a vulnerability to pharmacological inhibition of smarca4/2 |
| WO2025129116A1 (en) * | 2023-12-14 | 2025-06-19 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
| WO2026120044A1 (en) * | 2024-12-04 | 2026-06-11 | Astrazeneca Ab | Smarca2 degraders and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019249849C1 (en) * | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
| CA3150354A1 (en) * | 2019-09-12 | 2021-03-18 | Muralidhara Ramachandra | METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS |
-
2020
- 2020-10-26 EP EP20880820.4A patent/EP4054724A4/en not_active Withdrawn
- 2020-10-26 JP JP2022523943A patent/JP2023511471A/ja active Pending
- 2020-10-26 US US17/771,127 patent/US20230002367A1/en not_active Abandoned
- 2020-10-26 CN CN202080074772.3A patent/CN114599428A/zh active Pending
- 2020-10-26 WO PCT/US2020/057356 patent/WO2021086785A1/en not_active Ceased